P131 | New biomarkers for sepsis management in Medicine department

G. Rossoni¹, A. Franconi¹, I. Zagni¹, P. Carleo¹, A. Bonomini², M.G. Marin², F. Bonfante¹ | ¹UOC Medicina Generale, ASST del Garda, ²UOC Patologia Clinica e Medicina di Laboratorio, ASST del Garda, Italy

Premises and Purpose of the study: Since sepsis is a leading cause of hospitalized patients mortality, different diagnostic and prognostic biomarkers have been studied. Proadrenomedullina (MR-proADM) is the stable fragment of adrenomedullina, that plays an important role in microcirculation and endothelial cells’ function. ADM levels can significantly increase relating to disease’s severity. Heparin binding protein (HBP) is synthesized in activated neutrophils. During sepsis, HBP level increases significantly and correlates with the development of hypotension and organ dysfunction.
Materials and Methods: We evaluated 40 patients with sepsis. A blood sample was performed at admission (T0) and after 72 hours (T1). We analysed plasma concentration of MR-pro-ADm with LIAISON® BRAHMS MR-proADMTM and HBP with AB ANALITICA FIC testing procedures. Clinical evaluation done with NEWS score.
Results: 94% of patients had MR-proADM level >1.5nmol/L. We observed a media clearance of 0.52 nmol/L (SD 14.3) at T1. 13% of patients had HBP level >103.5 ng/dL, 60% is in the 28.1-103.5 ng/dL level, 27% in the 11-4-28.1 ng/dL level. The media clearance at T1 was 20.82 ng/dL, equally distributed in all the groups. Elevated levels of MR-proADM and HBP are detected in patients with NEWS score >7. In the medium risk group, the best clearance value of both biomarkers correlated with clinical conditions improvement.
Conclusions: MR-proADM and HBP testing could contribute to improve patients clinical mangement and prognostic assessment.